Therapeutic targeting of acute myeloid leukemia stem cells
For more than 50 years, investigators have considered a malignant stem cell as the potential origin of and a key therapeutic target for acute myeloid leukemia (AML) and other forms of cancer. The nature and existence of tumor-initiating cells for leukemia and other malignancies have long been the su...
Saved in:
| Published in: | Blood Vol. 129; no. 12; pp. 1627 - 1635 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
23.03.2017
|
| Subjects: | |
| ISSN: | 1528-0020 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | For more than 50 years, investigators have considered a malignant stem cell as the potential origin of and a key therapeutic target for acute myeloid leukemia (AML) and other forms of cancer.
The nature and existence of tumor-initiating cells for leukemia and other malignancies have long been the subject of intense and rigorous study; indeed, the promise of the potential to eradicate such cells is clear. However, until recently, deficiencies in our understanding of the nature of these cell populations, coupled with a limited ability to therapeutically exploit their weaknesses, have been limiting factors in realizing the goal of targeting leukemic stem cells (LSCs). Exciting new insights into the fundamental underpinnings of LSCs are now being made in an era in which drug development pipelines offer the potential to specifically target pathways of significance. Therefore, the focus in this new era, characterized by the confluence of understanding LSCs and the ability to target them, is shifting from "if it can be done" to "how it will be done." Moving from a theoretical stage to this hopeful era of possibilities, new challenges expectedly arise, and our focus now must shift to determining the best strategy by which to target LSCs, with their well-documented heterogeneity and readily evident intra- and interpatient variability. The purpose of this review is therefore both to summarize the key scientific findings pertinent to AML LSC targeting and to consider methods of clinical evaluation that will be most effective for identifying successful LSC-directed therapies. |
|---|---|
| AbstractList | For more than 50 years, investigators have considered a malignant stem cell as the potential origin of and a key therapeutic target for acute myeloid leukemia (AML) and other forms of cancer.
The nature and existence of tumor-initiating cells for leukemia and other malignancies have long been the subject of intense and rigorous study; indeed, the promise of the potential to eradicate such cells is clear. However, until recently, deficiencies in our understanding of the nature of these cell populations, coupled with a limited ability to therapeutically exploit their weaknesses, have been limiting factors in realizing the goal of targeting leukemic stem cells (LSCs). Exciting new insights into the fundamental underpinnings of LSCs are now being made in an era in which drug development pipelines offer the potential to specifically target pathways of significance. Therefore, the focus in this new era, characterized by the confluence of understanding LSCs and the ability to target them, is shifting from "if it can be done" to "how it will be done." Moving from a theoretical stage to this hopeful era of possibilities, new challenges expectedly arise, and our focus now must shift to determining the best strategy by which to target LSCs, with their well-documented heterogeneity and readily evident intra- and interpatient variability. The purpose of this review is therefore both to summarize the key scientific findings pertinent to AML LSC targeting and to consider methods of clinical evaluation that will be most effective for identifying successful LSC-directed therapies. For more than 50 years, investigators have considered a malignant stem cell as the potential origin of and a key therapeutic target for acute myeloid leukemia (AML) and other forms of cancer.1-4 The nature and existence of tumor-initiating cells for leukemia and other malignancies have long been the subject of intense and rigorous study; indeed, the promise of the potential to eradicate such cells is clear. However, until recently, deficiencies in our understanding of the nature of these cell populations, coupled with a limited ability to therapeutically exploit their weaknesses, have been limiting factors in realizing the goal of targeting leukemic stem cells (LSCs). Exciting new insights into the fundamental underpinnings of LSCs are now being made in an era in which drug development pipelines offer the potential to specifically target pathways of significance. Therefore, the focus in this new era, characterized by the confluence of understanding LSCs and the ability to target them, is shifting from "if it can be done" to "how it will be done." Moving from a theoretical stage to this hopeful era of possibilities, new challenges expectedly arise, and our focus now must shift to determining the best strategy by which to target LSCs, with their well-documented heterogeneity and readily evident intra- and interpatient variability. The purpose of this review is therefore both to summarize the key scientific findings pertinent to AML LSC targeting and to consider methods of clinical evaluation that will be most effective for identifying successful LSC-directed therapies. |
| Author | Jordan, Craig T Pollyea, Daniel A |
| Author_xml | – sequence: 1 givenname: Daniel A surname: Pollyea fullname: Pollyea, Daniel A organization: Division of Hematology, University of Colorado School of Medicine, Aurora, CO – sequence: 2 givenname: Craig T surname: Jordan fullname: Jordan, Craig T organization: Division of Hematology, University of Colorado School of Medicine, Aurora, CO |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28159738$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1j8lOwzAURS0EogP8AUJesjE8D0lcdqhikiqxKevIw3MJJHGInUX_niLK6m6Ors5ZkNM-9kjIFYdbzrW4s22MngngJePAylUJcnVC5rwQmgEImJFFSp8AXElRnJOZ0LxYVVLPyf32A0cz4JQbR7MZd5ibfkdjoMZNGWm3xzY2nrY4fWHXGJoydtRh26YLchZMm_DyuEvy_vS4Xb-wzdvz6_phw5yqVGbSg3UVSmW8D9pWoE1luRKVLY3VvgwHa1CAQQWtnDdcOM19CCAUigKFWJKbv99hjN8Tplx3Tfo1MD3GKdVcl0UhpJZwQK-P6GQ79PUwNp0Z9_V_r_gBG9pY9g |
| CitedBy_id | crossref_primary_10_1073_pnas_2003900117 crossref_primary_10_32604_oncologie_2022_025144 crossref_primary_10_1097_MOH_0000000000000485 crossref_primary_10_1182_blood_2023022202 crossref_primary_10_3390_diagnostics14222560 crossref_primary_10_3390_cancers12123742 crossref_primary_10_3390_cancers17111818 crossref_primary_10_1002_ajh_25556 crossref_primary_10_1002_hem3_45 crossref_primary_10_1111_bjh_16074 crossref_primary_10_1182_bloodadvances_2024013446 crossref_primary_10_1038_s41591_018_0233_1 crossref_primary_10_1186_s13045_020_00929_8 crossref_primary_10_2217_fon_2019_0373 crossref_primary_10_1007_s10238_025_01764_2 crossref_primary_10_1038_s41375_019_0386_z crossref_primary_10_3390_cancers13092161 crossref_primary_10_1038_s41598_019_40087_7 crossref_primary_10_1016_j_gene_2021_145903 crossref_primary_10_1158_0008_5472_CAN_21_4249 crossref_primary_10_3390_cancers13112816 crossref_primary_10_1007_s40259_021_00477_8 crossref_primary_10_1038_s41375_022_01697_9 crossref_primary_10_1038_s41586_023_06496_5 crossref_primary_10_1016_S0140_6736_18_31041_9 crossref_primary_10_1038_s41590_024_02063_w crossref_primary_10_3390_cancers12020357 crossref_primary_10_1002_hon_2516 crossref_primary_10_1016_j_xcrm_2025_102304 crossref_primary_10_1111_bjh_16104 crossref_primary_10_3390_cancers13194887 crossref_primary_10_1371_journal_pone_0209295 crossref_primary_10_1182_bloodadvances_2017004317 crossref_primary_10_1371_journal_pone_0278209 crossref_primary_10_3389_fonc_2023_1204895 crossref_primary_10_1182_blood_2019004397 crossref_primary_10_1002_cam4_3920 crossref_primary_10_1111_jcmm_14399 crossref_primary_10_32604_biocell_2021_014139 crossref_primary_10_3389_fimmu_2025_1571332 crossref_primary_10_1097_PPO_0000000000000577 crossref_primary_10_3390_cancers14071723 crossref_primary_10_3389_fonc_2022_890346 crossref_primary_10_1016_j_leukres_2018_08_003 crossref_primary_10_1016_j_phrs_2021_105616 crossref_primary_10_3390_ijms24119696 crossref_primary_10_1016_j_ccell_2020_04_017 crossref_primary_10_1038_s41375_022_01579_0 crossref_primary_10_1016_j_stem_2023_09_009 crossref_primary_10_1002_mog2_47 crossref_primary_10_1038_s41375_019_0657_8 crossref_primary_10_1038_s41375_024_02428_y crossref_primary_10_1080_10428194_2017_1410888 crossref_primary_10_1016_j_ccell_2019_06_003 crossref_primary_10_1016_S2352_3026_18_30031_0 crossref_primary_10_3389_fcell_2022_944760 crossref_primary_10_3904_kjim_2020_014 crossref_primary_10_2147_CMAR_S343033 crossref_primary_10_1111_bjh_15920 crossref_primary_10_1182_blood_2019003654 crossref_primary_10_3390_ijms24043062 crossref_primary_10_1038_s41467_020_14391_0 crossref_primary_10_3390_cancers15030720 crossref_primary_10_1002_cbf_3888 crossref_primary_10_1007_s12015_022_10349_5 crossref_primary_10_1158_0008_5472_CAN_18_3215 crossref_primary_10_1016_j_ccell_2018_10_005 crossref_primary_10_1016_j_jtbi_2020_110277 crossref_primary_10_1158_2159_8290_CD_19_0710 crossref_primary_10_1016_j_biopha_2025_117953 crossref_primary_10_14712_fb2019065010011 crossref_primary_10_1186_s12885_018_4097_z crossref_primary_10_3390_cancers12061596 crossref_primary_10_1007_s11899_018_0464_8 crossref_primary_10_3389_fimmu_2020_01280 crossref_primary_10_1002_cnr2_1139 crossref_primary_10_1038_s41467_025_61567_7 crossref_primary_10_3390_biomedicines6010022 crossref_primary_10_1016_j_stem_2021_02_013 crossref_primary_10_3390_cancers13030496 crossref_primary_10_1016_j_celrep_2024_114145 crossref_primary_10_1186_s12967_020_02384_y crossref_primary_10_3390_biomedicines11123248 crossref_primary_10_1002_hon_2651 crossref_primary_10_3390_hemato2030035 crossref_primary_10_1126_scitranslmed_abh2548 crossref_primary_10_1186_s40164_022_00282_1 crossref_primary_10_3762_bjnano_12_31 crossref_primary_10_3233_CBM_210042 crossref_primary_10_1016_j_stem_2023_07_001 crossref_primary_10_1016_j_biomaterials_2025_123091 crossref_primary_10_1016_j_stem_2020_07_021 crossref_primary_10_1080_14728222_2022_2083957 crossref_primary_10_1038_s41419_024_06865_6 crossref_primary_10_3389_fonc_2019_01058 crossref_primary_10_1158_1078_0432_CCR_25_0591 crossref_primary_10_1038_s43018_020_00126_z crossref_primary_10_1038_s41467_021_21650_1 crossref_primary_10_1016_j_cell_2019_01_031 crossref_primary_10_1016_j_bbcan_2017_03_010 crossref_primary_10_1016_j_compbiomed_2023_107093 crossref_primary_10_1016_j_jconrel_2018_07_024 crossref_primary_10_1038_s43018_022_00394_x crossref_primary_10_1007_s12015_020_10054_1 crossref_primary_10_1038_s41375_023_01916_x crossref_primary_10_1016_j_bbrc_2022_02_022 crossref_primary_10_1016_j_stem_2018_05_021 crossref_primary_10_1007_s11010_023_04861_6 crossref_primary_10_1016_j_stem_2018_11_017 crossref_primary_10_1002_hem3_70155 crossref_primary_10_1016_j_blre_2018_10_003 crossref_primary_10_1016_j_canlet_2024_217018 crossref_primary_10_1016_j_ygeno_2018_10_015 crossref_primary_10_1038_s41375_019_0635_1 crossref_primary_10_1111_bjh_70077 crossref_primary_10_1182_blood_2019001808 crossref_primary_10_15252_emmm_202115203 crossref_primary_10_1111_cas_15014 crossref_primary_10_1182_bloodadvances_2021005236 crossref_primary_10_15252_embj_201797773 crossref_primary_10_3389_fonc_2022_931050 crossref_primary_10_1016_j_scr_2020_102117 crossref_primary_10_3390_cancers15102713 crossref_primary_10_1016_j_xcrm_2025_102365 crossref_primary_10_3390_ijms24119667 crossref_primary_10_1016_j_stem_2022_12_006 crossref_primary_10_1080_10428194_2020_1817445 crossref_primary_10_3390_cancers12082182 crossref_primary_10_3390_ijms20174233 crossref_primary_10_7555_JBR_38_20240065 crossref_primary_10_1186_s13046_023_02841_8 crossref_primary_10_3390_metabo13040467 crossref_primary_10_1016_j_cell_2024_04_032 crossref_primary_10_1016_j_beha_2018_09_007 crossref_primary_10_1158_2159_8290_CD_19_1011 crossref_primary_10_1038_s41568_020_0260_3 crossref_primary_10_1016_j_stem_2020_04_010 crossref_primary_10_1002_JLB_2A0421_221R crossref_primary_10_3389_fonc_2020_00393 crossref_primary_10_3390_ijms241512037 crossref_primary_10_1016_j_exphem_2021_01_003 crossref_primary_10_1038_s41467_018_07584_1 crossref_primary_10_1038_s41556_022_01050_3 crossref_primary_10_1186_s12967_019_1904_5 crossref_primary_10_15252_emmm_202012670 crossref_primary_10_3389_fonc_2021_666829 crossref_primary_10_1080_14728222_2025_2500417 crossref_primary_10_1084_jem_20240587 crossref_primary_10_1158_2159_8290_CD_22_1297 crossref_primary_10_1053_j_semdp_2023_04_004 crossref_primary_10_1002_gcc_22805 crossref_primary_10_1016_j_apsb_2020_06_012 crossref_primary_10_1089_ars_2017_7326 crossref_primary_10_1038_s41375_024_02358_9 crossref_primary_10_1182_blood_2021013201 crossref_primary_10_1016_j_blre_2022_100950 crossref_primary_10_1177_1559325819887048 crossref_primary_10_1080_17474086_2018_1549479 crossref_primary_10_3389_fonc_2018_00041 crossref_primary_10_1172_JCI184665 crossref_primary_10_1038_s41467_022_33861_1 crossref_primary_10_1016_j_exphem_2018_08_005 crossref_primary_10_1182_bloodadvances_2020003022 crossref_primary_10_3389_fonc_2020_584766 crossref_primary_10_1186_s40164_021_00221_6 crossref_primary_10_1002_adfm_202411439 crossref_primary_10_1002_cyto_a_24284 crossref_primary_10_1002_hon_2615 crossref_primary_10_1016_j_jbior_2019_100652 crossref_primary_10_1097_MOH_0000000000000692 crossref_primary_10_1038_s41556_024_01548_y crossref_primary_10_1158_1078_0432_CCR_20_2540 crossref_primary_10_1182_blood_2024025618 crossref_primary_10_1186_s13045_021_01084_4 crossref_primary_10_1002_ctm2_154 crossref_primary_10_1182_blood_2021010721 crossref_primary_10_1016_j_drudis_2018_05_040 crossref_primary_10_1126_scitranslmed_adk1731 crossref_primary_10_1038_s41467_021_26420_7 crossref_primary_10_1038_s41467_020_14590_9 crossref_primary_10_1002_ijc_34243 crossref_primary_10_1016_j_bneo_2025_100135 crossref_primary_10_1515_hsz_2021_0286 crossref_primary_10_3390_cancers13153753 crossref_primary_10_1007_s00277_021_04602_z crossref_primary_10_1038_s41375_020_0773_5 crossref_primary_10_1182_bloodadvances_2019000357 crossref_primary_10_3390_cancers15102866 crossref_primary_10_1038_s41419_025_07831_6 |
| ContentType | Journal Article |
| Copyright | 2017 by The American Society of Hematology. |
| Copyright_xml | – notice: 2017 by The American Society of Hematology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2016-10-696039 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| EndPage | 1635 |
| ExternalDocumentID | 28159738 |
| Genre | Journal Article Review |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFETI AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c474t-3d0bc7e34addf8b708a7b1427b6ab8d6f016040ef4f84cda12c81dff024e25e22 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 226 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000397297300013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Sat Sep 27 21:58:48 EDT 2025 Wed Feb 19 02:30:37 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | 2017 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-3d0bc7e34addf8b708a7b1427b6ab8d6f016040ef4f84cda12c81dff024e25e22 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | https://ashpublications.org/blood/article-pdf/129/12/1627/1398769/blood696039.pdf |
| PMID | 28159738 |
| PQID | 1865523830 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1865523830 pubmed_primary_28159738 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-03-23 20170323 |
| PublicationDateYYYYMMDD | 2017-03-23 |
| PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-23 day: 23 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2017 |
| SSID | ssj0014325 |
| Score | 2.616847 |
| SecondaryResourceType | review_article |
| Snippet | For more than 50 years, investigators have considered a malignant stem cell as the potential origin of and a key therapeutic target for acute myeloid leukemia... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1627 |
| SubjectTerms | Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - pathology Molecular Targeted Therapy - methods Molecular Targeted Therapy - trends Neoplastic Stem Cells - pathology Signal Transduction - drug effects |
| Title | Therapeutic targeting of acute myeloid leukemia stem cells |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28159738 https://www.proquest.com/docview/1865523830 |
| Volume | 129 |
| WOSCitedRecordID | wos000397297300013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LS8MwGP_wrRcf8zVfRBBvZTHJmtSLTFE8uLHDlN1KmiYw1HbaTfC_90vbsZsIXkIugTT5-v1--Z4AF2mYCGudDEIWGd_CLA0SF7UDkTglJVeWl97zlyfZ66nhMOrXBreiDquc6cRSUae58Tby1pXPoER84fRm_BH4rlHeu1q30FiEZY5Uxod0yeHciyA4a9fpckijW1UoOCJe6JVPiNyd_0IsS4B52Prv1rZhs6aWpFPJwg4s2KwBu50Mn9Xv3-SSlMGepRW9Aau3s9n63azlWwPWurWnfReuB_PELFKFiyPIkdwRbaYTS96_7Vs-Ssmbnb7iek18QWji3QDFHjw_3A_uHoO6z0JghBSTgKc0MdJygbrOqURSpaW3Dckk1IlKQ-er0AlqnXBKmFRfMYMs1zmEd8valrF9WMryzB4C0VTig86FiI1GRKgNqaWGKZ0qipfPdBPOZ0cY47f5XenM5tMinh9iEw6qe4jHVcGNmCkkXSg4R39YfQwbzCMv5QHjJ7Ds8C-2p7Biviaj4vOsFBAce_3uD2pDxjg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+targeting+of+acute+myeloid+leukemia+stem+cells&rft.jtitle=Blood&rft.au=Pollyea%2C+Daniel+A&rft.au=Jordan%2C+Craig+T&rft.date=2017-03-23&rft.eissn=1528-0020&rft.volume=129&rft.issue=12&rft.spage=1627&rft.epage=1635&rft_id=info:doi/10.1182%2Fblood-2016-10-696039&rft.externalDBID=NO_FULL_TEXT |